Brief: Syros Provides Update on SELECT-AML-1 Phase 2 Clinical Trial

Syros Pharmaceuticals

12/08/2024 21:46

Aug 12 (Reuters) - Syros Pharmaceuticals Inc  SYRS.O :
    * SYROS PROVIDES UPDATE ON SELECT-AML-1 PHASE 2 CLINICAL
TRIAL
    * SYROS PHARMACEUTICALS INC: WILL DISCONTINUE ENROLLMENT IN
SELECT-AML-1 PHASE 2 CLINICAL TRIAL
    * SYROS PHARMACEUTICALS INC - SELECT-MDS-1 TRIAL PASSED A
PRESPECIFIED FUTILITY ANALYSIS IN Q1 OF 2024 AND IS CONTINUING
AS PLANNED
    * SYROS PHARMACEUTICALS INC: NO NEW SAFETY SIGNALS
ASSOCIATED WITH
USE OF TAMIBAROTENE IN COMBINATION WITH VENETOCLAX AND
AZACITIDINE

Source text for Eikon:  ID:nBw38GG1ma 
Further company coverage:  SYRS.O 

 ((Reuters.Briefs@thomsonreuters.com;))